Biocon Biologics not only denied allegations of bribery, but said that the rationale for waiving phase-3 clinical trials for its Insulin Aspart injection was based on Indian regulatory guidance.
The company
SEC recommendation in accordance with guidelines: Biocon Biologics
The company said its product approvals are backed by science and clinical data
 "Biocon")
Premium
The company said it condemns all acts of corruption and bribery and is cooperating with the investigating agency.
First Published: Jun 22 2022 | 1:15 AM IST
Key stories on business-standard.com are available only to BS Premium subscribers.
Register to read more on Business-Standard.com
